We are a full service contract research organization, ready to serve your needs!

CONTACT US!

REGULATORY AFFAIRS

Libra Medical will provide you with a comprehensive, global regulatory strategy for all classes of medical devices, IVD, and Biologics. 


QUALITY ASSURANCE

Libra Medical will supply you with a Quality Assurance System that will be customized specifically to meet your needs


CLINICAL TRIAL MANAGEMENT

Libra Medical is a full service Contract Research Organization offering services for all your clinical trial needs


ABOUT LIBRA MEDICAL

A Full Service Contract Research Organization

We provide Regulatory Affairs, Clinical Trial Management and Quality Assurance Services.  In addition, Libra Medical offers full hosting and management of MAESTRO CTMS Clinical Trial Management System.  MAESTRO is a full-featured, integrated data and trial management system at an affordable price.

 We provide customized programs and technology solutions through our resident expertise.

GET IN TOUCH
Libra Medical, Inc. was founded in January 2007 as a full Contract Research Organization (CRO) providing innovative solutions to the Regulatory Affairs, Clinical Research, and Quality Assurance functions within life science companies. Our clients include well-established global medical device companies as well as emerging medical device companies. 

LEARN MORE
Dr. Sew-Wah Tay founded Libra Medical Inc. in January 2007 after 20 years of experience in the medical device industry.  Dr. Tay has served in various capacities in R&D and Clinical Affairs in the medical device industry. 

LEARN MORE 

TESTIMONIALS

Ann K., Cardiovascular Systems Inc.

“Libra Medical’s work on our clinical studies is impeccable.  They are responsive, knowledgeable and congenial colleagues.”

Kari Cierzan, American Medical Systems, Inc.

“…not only met our deadlines but the quality of and manner in which the data were gathered allowed us to speed up our launch timing. ”

Tom Ressemann, Entellus Medical

“With Libra as our partner, I could rest at night, knowing that our regulatory and clinical strategy was well defined. ”